Kazia Therapeutics (KZIA) appointed Sudha Rao as Chief Scientific Officer, or CSO. Dr. Rao has more than 20 years of experience spanning pharmaceutical R&D, biotechnology, and early clinical development. She currently holds a professorial appointment and leads the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer Medical Research Institute and previously held senior scientific roles at Sanofi/Rhone-Poulenc in the UK. She is the founder and former Chief Scientific Officer of EpiAxis Therapeutics. At Kazia, Dr. Rao will lead all research and development activities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics initiated with a Buy at Laidlaw
- Kazia Therapeutics Licenses SETDB1 Epigenetic Platform to Bolster Oncology Pipeline
- Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer
- Kazia Therapeutics Announces Board Changes and AGM Outcomes as It Highlights Oncology Pipeline
- Kazia Therapeutics Taps Leerink for New ATM Facility as Cash Bolstered by Late-2025 PIPE